VivoSim Labs (NASDAQ: VIVS) is a life sciences technology company specializing in the development and commercialization of advanced microphysiological systems, often referred to as “organ-on-a-chip” platforms. These in vitro models are designed to replicate key aspects of human tissue function, providing researchers with physiologically relevant data during drug discovery, toxicology assessment, and disease modeling. By integrating microfluidics, 3D cell culture and real-time biosensing, VivoSim Labs aims to bridge the gap between preclinical studies and human clinical outcomes.
The company’s core product lineup includes modular systems such as LiverSim™, CardioSim™ and NeuroSim™, each tailored to simulate the unique cellular and mechanical environment of its respective organ. These platforms support continuous monitoring of cellular responses, enabling end-users to measure parameters like metabolic activity, contractility and barrier integrity under controlled flow conditions. VivoSim Labs also offers custom assay development, software analytics tools and ongoing technical support to academic institutions, pharmaceutical companies and contract research organizations (CROs).
Founded in 2017 by a team of bioengineers and tissue-culture specialists, VivoSim Labs is headquartered in Cambridge, Massachusetts, with satellite facilities in London and Singapore to serve the global life sciences market. The company collaborates with leading universities and industrial partners to validate its models against clinical data, streamline regulatory adoption and expand its portfolio into emerging areas such as immuno-oncology and precision medicine. This international footprint enables VivoSim Labs to address diverse research needs across North America, Europe and Asia.
Under the leadership of CEO Dr. Emily Zhou, a veteran in biomedical instrumentation, VivoSim Labs has assembled a management team with deep expertise in microfluidics, pharmacology and commercial development. The company holds a growing portfolio of patents covering microchannel design, tissue scaffolding methods and integrated sensor technologies. Through strategic partnerships and continued R&D investment, VivoSim Labs seeks to reduce reliance on animal testing, accelerate drug development timelines and deliver more predictive preclinical data to its customers.
AI Generated. May Contain Errors.
Free VIVS Stock Alerts